Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Online Parkinson's community launched

Britannia Pharmaceuticals' initiative focuses on mid- to late-stages of the disease

A new online community for patients with Parkinson's disease, their carers and healthcare professionals has been launched by Britannia Pharmaceuticals.

The UK firm, which is part of the Stada group, will use The Parkinson Hub to share news and best practice about Parkinson's disease, with an emphasis on the disease's mid- to late-stages.

The community provides an overview of the disease, including the nature of the condition and information on available treatment options.

Britannia's own product in the area is its apomorphine treatment, which is indicated for motor fluctuations (the so-called “on-off” phenomena) in Parkinson's patients whose disease is not sufficiently controlled by oral anti-Parkinson medications.

It is marketed as APO-go in the UK and Europe, APOKYN in the United States and Japan, APOKYN in France and Apomine in Australia.

The new community also highlights inspirational examples of celebrities, such as Michael J Fox, and 'everyday heroes' who are “living their lives to the full” despite suffering from Parkinson's.

Britannia is accompanying the community's launch with its new PD Quality of Life resource, which enables people with Parkinson's to identify and understand those areas in their life most impacted by their condition.

Britannia said the resource, which currently available in English, Spanish and German, would empower patients “to have a more informed discussion about their well-being and unique needs with their healthcare professionals and care teams”.

29th April 2013

From: Marketing, Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...
New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....

Infographics